Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24

Rhea-AI Summary

Bio-Path Holdings (NASDAQ: BPTH) has received updated coverage from Stonegate Capital Partners for Q1 2024. Key highlights include the ongoing Phase 2 trial of Prexigebersen, a lead candidate in their pipeline. The company also boasts numerous other drug candidates undergoing development. Additionally, Bio-Path raised $3.5 million in 2024, ensuring they have sufficient liquidity to support their operations and ongoing trials.

Positive

• Prexigebersen Phase 2 trial is currently underway.
• Numerous drug candidates are in the BPTH pipeline.
• Raised $3.5 million in 2024, providing sufficient liquidity.

Negative

• No specific details on the progress or results of the Prexigebersen Phase 2 trial.
• The $3.5 million raised may not be sufficient for long-term needs if further trials or developments are delayed or cost more than anticipated.

Dallas, Texas--(Newsfile Corp. - June 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q1 2024.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Prexigebersen Phase 2 underway
• Numerous drug candidates in the BPTH pipeline
• $3.5M of funds raised in 2024, giving sufficient liquidity

Click image above to view full announcement.

---

About Stonegate

Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking, equity research and capital raising for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/211731

FAQ

What is Bio-Path Holdings' stock symbol?

The stock symbol for Bio-Path Holdings is BPTH.

What is the latest update on Prexigebersen?

Prexigebersen is currently in Phase 2 trial as of Q1 2024.

How much funding did Bio-Path Holdings raise in 2024?

Bio-Path Holdings raised $3.5 million in 2024.

What is the status of Bio-Path Holdings' drug pipeline?

Bio-Path Holdings has numerous drug candidates in development.

Who provided the updated coverage on Bio-Path Holdings for Q1 2024?

Stonegate Capital Partners provided the updated coverage.